Sanguina Raises $2.8M in Series A Funding to Drive Innovation in Home-Based Testing and Wellness Management

PEACHTREE CORNERS, Ga.–( BUSINESS WIRE)–Sanguina, a leading biotech company focused on providing rapid home-based testing and management solutions, announced today the successful completion of its  $2.8m Series A funding round . Led by  Veritus Holdings , the round saw participation from notable investors, including George Hornig of The Seed Lab and Stephen Ippolito of Veritus Holdings. The funding will be used to accelerate the development and expansion of Sanguina’s innovative blood health management digital and at-home-based platforms.

Sanguina’s mission is to empower individuals by creating a  platform of accessible tools for diagnosing, monitoring, and managing wellness and chronic conditions  from the comfort of their own homes. Founded in 2019 as a spin-off from prestigious institutions such as the Georgia Institute of Technology, Emory University, Children’s Healthcare of Atlanta, and the Centers for Disease Control and Prevention (CDC), Sanguina has quickly made a mark in the biotech sector.

Sanguina logo

George Hornig and Stephen Ippolito of The Seed Lab and Veritus Holdings join Forbes 30u30 inventors and Sanguina co-founders Erika Tyburski and Rob Mannino, PhD, and world-renowned hematologist, Wilbur Lam, MD, PhD, on a Board with knowledge spanning decades in the healthcare, consumer behavior, consumer experience, and financial services industries.

Sanguina’s flagship product, the  AnemoCheck  app, is a digital health platform that estimates hemoglobin levels and aids users in managing anemia. In addition to the app, Sanguina boasts an  FDA-cleared  point-of-care test, which the company plans to expand for home use later this year.  Anemia, characterized by low hemoglobin levels, affects over 1.6bn individuals each year and has always been a marker of both illness and wellness, as it coexists with many chronic diseases and can guide treatment regimens.  In June, two large, independent peer-reviewed published studies featured in the  Annals of Internal Medicine  and  Journal of the American Medical Association (JAMA)  revealed that anemia is a chronic problem for very large categories of Americans, ranging from those taking daily aspirin to women and girls who have iron deficiency from a variety of conditions. Additionally,  clinical hematologists reviewed several studies on anemia  and reveal that chronic health inequity has caused many women and minorities to normalize their anemia.

With advancements in home testing and artificial intelligence, the management of anemia and other chronic conditions is moving towards preventive and personalized medicine. The Series A funding round will enable Sanguina to enhance its existing product suite with artificial intelligence and machine learning models, improving utility, performance, and accessibility. Furthermore, this funding will pave the way for the introduction of new biomarkers and indications, including home-based testing for circulation, dehydration, for management of other chronic diseases.

“We are thrilled to have secured this funding to further our mission of providing accessible tools for managing wellness and chronic conditions,” said Erika Tyburski, Co-founder and CEO of Sanguina. “This investment will enable us to enhance our technology and platforms, bringing us closer to our vision of becoming a leading provider of home-based testing solutions.”

With the successful launch of  anemia   management  through the AnemoCheck app and point-of-care test, Sanguina has  taken a major stride towards  revolutionizing home-based testing and personalized disease management.

About Sanguina, Inc.

Sanguina, Inc.  (Sanguina)  is a leading biotech company focused on advancing accessible digital and at-home health platforms for rapid home-based testing and disease management. Founded in 2019, Sanguina aims to empower individuals by providing innovative solutions for diagnosing, monitoring, and managing wellness and chronic conditions. With a team of experienced scientists, engineers, and healthcare professionals, Sanguina is committed to positively impacting global healthcare. To learn more about Sanguina, please visit  sanguina.com  or on social media through  Instagram,  Facebook,  Twitter, or  LinkedIn.

Website:  www.sanguina.com

Who is Sanguina  video

Contacts

Jessica Tackett
Director of Marketing
jessy.tackett@sanguina.com

BIO Supports PDUFA VIII Commitment Letter and Urges Timely Reauthorization

August 17, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter: “For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients. “Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency. “Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.” The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033. Learn More about PDUFA and the PDUFA VIII commitment letter HERE .

Georgia Life Sciences Announces 2026 Golden Helix Award Honorees

August 10, 2026
Award recipients will be recognized at the Golden Helix Awards Ceremony on August 25 ATLANTA, Ga. – Georgia Life Sciences today announced the recipients of the 2026 Golden Helix Awards, recognizing the individuals, organizations, partnerships, and investments that are advancing innovation, improving patient care, strengthening Georgia's economy, and shaping the future of the state's life sciences ecosystem. The honorees will be celebrated during the Georgia Life Sciences Summit Welcome Reception and Golden Helix Awards Ceremony on Tuesday, August 25, at the Sandy Springs Performing Arts Center, kicking off Georgia's premier gathering of life sciences leaders ahead of the Summit on Wednesday, August 26. "For nearly two decades, the Golden Helix Awards have celebrated the people and organizations whose vision, collaboration, and commitment continue to elevate Georgia as a global leader in life sciences," said Maria Thacker Goethe, President & CEO of Georgia Life Sciences. "This year's recipients represent the extraordinary innovation taking place across our state—from groundbreaking research and transformative investments to workforce development and community impact. We are proud to recognize their achievements and the lasting difference they are making for patients, our economy, and the future of healthcare." 2026 Golden Helix Award Honorees Phoenix Award · Micron Biomedical, Emory University, and CDC – Industry-Academic Partnership Innovation Awards · Dr. Kyle Johnsen, University of Georgia · Focused Cryo Community Awards · Angela Gill Nelms, Biolocity · Frugal Science Academy · Jessica King Holden, Gwinnett Regional Science, Engineering + Innovation Fair · Dr. Marlo Vernon, Augusta University Deal of the Year Awards Economic Development · UCB · Shriners Children's Research Institute and Georgia Tech Acquisition · LymphaTech & Tactile Medical · Avanos Medical Financing · Altesa BioSciences Federal Grant · HEAL: Healthy Ameliorated Lymphatics, Georgia Institute of Technology · Manus & U.S. Department of Health and Human Services Administration for Strategic Preparedness and Response (HHS/ASPR) Emerging Leader of the Year · Dr. Ryan Devine, Medical Innovation Hub, Georgia Tech Legislator of the Year · Rep. Matt Dubnik (R-29) Teacher of the Year · Ana White, DeKalb High School of Technology North at Cross Keys The Golden Helix Awards recognize excellence across Georgia's life sciences ecosystem, honoring breakthrough scientific discoveries, strategic partnerships, commercial achievements, community leadership, and investments that strengthen the state's position as a national leader in biotechnology, medical technology, pharmaceuticals, research, and advanced manufacturing. The awards ceremony serves as the opening event of the 2026 Georgia Life Sciences Summit, bringing together executives, researchers, entrepreneurs, investors, and healthcare leaders, and academic institutions from across the state to celebrate innovation and explore opportunities shaping the future of Georgia's life sciences industry. The Georgia Life Sciences Summit will take place on Wednesday, August 26, at the Sandy Springs Performing Arts Center, featuring nationally recognized speakers, executive panels, CEO spotlights, networking opportunities, and the Solutions Corridor showcasing organizations driving the industry's continued growth. To learn more about the Georgia Life Sciences Summit or to register, visit https://www.galifesciences.org/summit.

Students can attend the Georgia Life Sciences Summit for just $150?

August 7, 2026
One of the biggest benefits of becoming a Georgia Life Sciences Student Member is access to discounted registration for Georgia's premier life sciences conference—bringing together CEOs, researchers, entrepreneurs, investors, and innovators from across the state. Better yet, Student Membership is only $25 per year , making it one of the best investments you can make in your future. The Georgia Life Sciences Emerging Leaders Network (ELN) is the official student membership community of Georgia Life Sciences, created to connect students, postdoctoral researchers, and early-career professionals with Georgia's thriving life sciences ecosystem. As an ELN member, you'll build meaningful peer-to-peer relationships, engage with industry leaders, explore career opportunities, and gain access to professional development programs designed to help you launch a successful career in the life sciences. As a member, you'll have opportunities to: Connect with fellow students, postdocs, and emerging professionals from across Georgia. Expand your network through peer-to-peer engagement and professional networking events. Learn from industry leaders and gain exposure to Georgia's life sciences ecosystem. Participate in workforce and career development programming. Access Career Connections Student members also receive exclusive access to the Georgia Life Sciences Career Connections LinkedIn Group , where you can: Discover internships and job opportunities. Connect with employers, recruiters, and industry professionals. Stay informed about career fairs, networking events, and workforce initiatives. Engage with a growing community of future life sciences leaders. Student Member Benefits Georgia Life Sciences Student Membership: $25/year Georgia Life Sciences Summit Registration: $150 Access to the Emerging Leaders Network Career Connections LinkedIn Group Networking events and professional development opportunities Industry news, workforce resources, and member communications Whether you're exploring careers in biotechnology, medical devices, pharmaceuticals, diagnostics, digital health, or research, Georgia Life Sciences connects you to the people and opportunities that can help shape your future. Join today . Build your network. Advance your career.
MORE POSTS